Holen Sie sich die Stockscreener-App
82.34
2.00%
-1.68
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
What is the long term forecast for Kymera Therapeutics Inc. stock2025 Big Picture & Weekly High Return Stock Opportunities - mfd.ru
Kymera Therapeutics Touts Once-Daily Oral “Biologics-Like” KT-621 at Guggenheim Conference - Yahoo Finance
Kymera Therapeutics discloses new STAT6 inhibitors - bioworld.com
Will Kymera Therapeutics Inc. face regulatory challenges2025 Key Highlights & Expert Approved Trade Ideas - mfd.ru
What is Kymera Therapeutics Inc. s 5 year growth outlookMarket Sentiment Summary & Weekly Top Gainers Alerts - mfd.ru
What’s the outlook for Kymera Therapeutics Inc.’s sectorAnalyst Downgrade & Smart Investment Allocation Insights - mfd.ru
Kymera at Guggenheim Biotech Summit: Exploring Oral Drug Potential By Investing.com - Investing.com Canada
Is Kymera Therapeutics Inc. a strong candidate for buy and holdProduct Launch & AI Based Buy and Sell Signals - mfd.ru
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Candriam S.C.A. - MarketBeat
How Kymera Therapeutics Inc. stock performs in weak economyIndex Update & Fast Entry and Exit Trade Plans - mfd.ru
KT-621 Phase 2b Expansion Across Type 2 Diseases Could Be A Game Changer For Kymera Therapeutics (KYMR) - Sahm
Aug Update: What makes Kymera Therapeutics Inc. stock attractive to growth fundsDividend Hike & Free Safe Capital Growth Stock Tips - mfd.ru
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Biotech Innovator with 47.7% Upside Potential - DirectorsTalk Interviews
Certain Warrants of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Certain Common Stock of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
CEO Moves: Will FATN outperform small cap indexesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - baoquankhu1.vn
Kymera Therapeutics (KYMR) Is Up 7.0% After Advancing Dual Phase 2b Trials for KT-621 - Sahm
Smart Money: What are Kymera Therapeutics Incs earnings expectationsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
KYMR initiates dosing in mid-stage asthma study of lead candidate - MSN
Kymera Therapeutics to Participate in Upcoming February Investor Conferences - Investing News Network
Kymera Therapeutics (KYMR): A Biotech Stock with 54% Potential Upside Amid Innovative Protein Degradation Focus - DirectorsTalk Interviews
(KYMR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings) - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating for Kymera Therapeutics (KYMR) with $ - GuruFocus
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Knights of Columbus Asset Advisors LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Federated Hermes Inc. Makes New Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 - Yahoo Finance
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate - Yahoo Finance
Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader By Investing.com - Investing.com South Africa
Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader - Investing.com India
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network
Kymera Therapeutics Announces First Patient Dosed In Breadth Phase 2B Asthma Clinical Trial Of KT-621, A First-In-Class, Oral Stat6 Degrader - TradingView
Analyst Barclays Raises Price Target for Kymera Therapeutics (KY - GuruFocus
Aug Movers: Can Kymera Therapeutics Inc benefit from deglobalization2025 Fundamental Recap & Weekly Breakout Watchlists - baoquankhu1.vn
Kymera Therapeutics (KYMR) Stock Analysis: Exploring A 64% Upside Potential - DirectorsTalk Interviews
What is the earnings history of Kymera Therapeutics Inc.2025 Trading Recap & Reliable Price Breakout Signals - mfd.ru
Responsive Playbooks and the KYMR Inflection - Stock Traders Daily
Aug Volume: What is the long term forecast for Kymera Therapeutics Inc stockWall Street Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Assessing Kymera Therapeutics (KYMR) Valuation After Milestone Updates For KT-621 And Partnered IRAK4 Programs - Sahm
Is BRID stock overvalued or fairly pricedJuly 2025 Sentiment & Community Trade Idea Sharing Platform - baoquankhu1.vn
Kymera Therapeutics director Esposito sells $373k in shares By Investing.com - Investing.com Nigeria
Kymera Therapeutics director Esposito sells $373k in shares - Investing.com
This drugmaker's stock is soaring over 40% Monday - MSN
Signal Recap: Does Loop Industries Inc outperform in volatile marketsMarket Activity Report & Safe Swing Trade Setups - baoquankhu1.vn
Exit Recap: Can Kymera Therapeutics Inc benefit from deglobalizationJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Portfolio Update: What is Kymera Therapeutics Incs 5 year growth outlookWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Kymera Therapeutics, Inc. (KYMR) up 28% in 3M, analysts see further upside - MSN
Is Kymera Therapeutics (KYMR) Turning Its Immunology Pipeline Into a Durable Platform Advantage? - Sahm
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) - Benzinga
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside - Finviz
Muted and missing M&As: JPM deals absent in 2026 - BioWorld MedTech
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):